major depressive disorder

This page shows the latest major depressive disorder news and features for those working in and with pharma, biotech and healthcare.

Depression drug failure adds to Allergan's woes

Axe hangs over remaining monotherapy and suicidality trials. Allergan’s novel treatment for major depressive disorder (MDD) rapastinel has failed in three pivotal phase 3 studies. ... The misfiring of rapastinel is a major blow for the company’s most

Latest news

J&J’s Spravato breaks depression drought at FDA

major depressive disorder (MDD) who haven’t seen any improvement in mood after trying two different drugs previously.
Sage raises $575m ahead of FDA review date for Zulresso

It also has an FDA breakthrough designation for this indication. The follow-up is also being developed in a phase 3 programme as a short oral course for major depressive disorder, ... It is also in earlier-stage studies for MDD plus insomnia as a
FDA panel backs J&J’s new-class antidepressant

as an add-on therapy to orally-administered antidepressants in people with major depressive disorder (MDD) who don’t respond to oral drugs alone.
Janssen submits esketamine in Europe for treatment resistant depression

Esketamine is a glutamate receptor modulator, for treatment-resistant depression (TRD) in adults with Major Depressive Disorder (MDD). ... Mathai Mammen. “Major Depressive Disorder affects approximately 40 million people across Europe, and is the
Sage surges after depression drug gets rapid path to approval

SAGE-217 is being tested in post-partum depression (PPD) that affects mother after childbirth as well as major depressive disorder (MDD), for which Sage reported positive phase 2 results last ... SAGE-217, if successfully developed and approved, may

More from news
Approximately 6 fully matching, plus 52 partially matching documents found.

Latest Intelligence

Leo has its eyes on the prize

condition and the promise of major therapeutic breakthroughs. ... major depressive disorder and iron-deficiency anaemia.
Pharma deals continue to slide

74.5 (upfront 65). Cerecor (US). J&J/Janssen (US). Asset acquisition. CERC-501 phase II oral kappa opioid receptor antagonist for adjunctive treatment of major depressive disorder.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Director – Healthcare PR: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

PR Associate Director – Consumer Health & Beauty: Salary TBC

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Account Director, Medical Education: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Medical Writer: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Medical Writer: Competitive salary and benefits

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Subscribe to our email news alerts

PMHub

Add my company

Red Health

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...